Remus Pharmaceuticals P/B Ratio
REMUS • Price-to-Book ratio analysis and book value breakdown
Current P/B Ratio
3.27
High Valuation
High - Premium to book value, growth expectations or asset-light model
Current Valuation Metrics
P/B Ratio
3.27
Current Price
₹
Book Value/Share
₹471.67
Exchange
None
Book Value Breakdown (2025)
Balance Sheet Components
Total Equity
₹283 Cr
Share Capital
₹6 Cr
Reserves & Surplus
₹250 Cr
Outstanding Shares
6,000,000
Book Value per Share
₹471.67
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
-0.09
Sector Median
0.65
Sector Rank
#11 of 50
Sector Percentile
22.0%
Key P/B Ratio Insights for Remus Pharmaceuticals
- Stock appears overvalued with PB of 3.27, trading at significant premium to book value
- Trading at high premium to book value - indicates strong growth expectations or asset-light business model
- Trading at premium to sector average PB of -0.09
View the current stock price of Remus Pharmaceuticals for more insights.
Related Pages for Remus Pharmaceuticals
Additional stock information and data for REMUS
Sector P/B Ratio Comparison
Comparing Remus Pharmaceuticals with other companies in Healthcare sector
Sector Average
-0.09
Sector Median
0.65
Lowest P/B
-12.71
Highest P/B
1.2
Companies
50
| Company | Symbol | P/B Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sun Pharma Advanced Rese… | SPARC | -12.71 | ₹4,389 | Low |
| Span Divergent | SDL | -6.32 | ₹19 | Low |
| Oxygenta Pharmaceutical | OXYGENTAPH | -5.54 | ₹203 | Low |
| Satiate Agri | SATAGRI | -3.39 | ₹8 | Low |
| Adline Chem Lab | ADLINE | -3.03 | ₹5 | Low |
| Bharat Immunologicals | BIBCL | -2.47 | ₹95 | Low |
| Parmax Pharma | PARMAX | -2.15 | ₹12 | Low |
| Krebs Biochemicals & Ind… | KREBSBIO | -0.96 | ₹154 | Low |
| Triochem Products | TRIPR | 0.04 | ₹0 | Low |
| Murae Organisor | MURAE | 0.27 | ₹57 | Low |